A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects

Trial Profile

A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs PF 6263276 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Nov 2017 Results from the single and multiple ascending dose (SAD, MAD) studies of PF-06650833 in healthy subjects assessing safety and efficacy, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 16 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrial.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top